Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMP-SMX for Pneumocystis jirovecii in AECOPD (TOPIC)
NCT05418777Phase 2Terminated
- Sponsor
- Corewell Health
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing TMP-SMX Arm with Placebo Arm (2 arms). Primary endpoint: COPD Assessment Test at 3 months. Started Sep 2022; status: terminated.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05418777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418777.